A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

by Mariane Teodoro Fernandes, Jacob J Adashek, Carmelia Maria Noia Barreto, Ana Cláudia Barbin Spinosa, Barbara de Souza Gutierres, Gilberto Lopes, Auro del Giglio, Pedro Nazareth Aguiar Jr
Published 2018-11-01